
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is viewed favorably because its June 2 CRL for CTx-1301 cited only CMC issues, not safety or efficacy concerns, preserving the core regulatory value of its once-daily ADHD program and supporting a credible resubmission path. The company’s $28.4M cash balance in 2Q26 provides runway into mid-2027, while the July 21 Prasco distribution agreement and patent protection through 2042 strengthen its commercialization and intellectual-property profile. With ADHD medication sales reaching about $18 billion in 2020 and CTx-1301/CTx-1302 targeting large pediatric and adult populations, the platform offers meaningful upside if approval is achieved after resubmission.
Bears say
Cingulate is viewed negatively because its lead asset CTx-1301 still faces unresolved FDA issues, including three Form 483 observations and the need for both CMC and facility remediation, making approval dependent on Bend Bioscience execution and a possible second inspection. The company’s launch outlook is therefore fragile, with any delay potentially pushing commercialization beyond the currently projected 3Q27, while its broader pipeline also carries regulatory, clinical, reimbursement, and partnership risks. Financially, it remains pre-revenue and unprofitable, reporting a $9.3 million net loss in Q1 2026 and a $5.9 million net loss in Q2 2026, with no guidance and ongoing dilution risk.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cingulate (CING) Forecast
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares